69P Biomarker-driven TAM RTK inhibitor plus immunotherapy would benefit NSCLC in first-line setting: Implications from phase III ORIENT-11 trialA. Li, L. Luo, Y. Zhou,W. Du, Z. Yu,W.F. Fang, Y. Yang, L. Zhang, S.D. HongESMO Open（2024）引用 0|浏览10暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
